Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19)

Next Previous
Trial Profile

Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Conestat alfa (Primary)
  • Indications Acute lung injury; Adult respiratory distress syndrome; COVID 2019 infections; COVID-19 pneumonia
  • Focus Therapeutic Use
  • Acronyms PROTECT-COVID-19

    • Most Recent Events

    • 01 Nov 2021 Status changed from active, no longer recruiting to discontinued.
    • 13 Sep 2021 According to a Pharming Group NV media release, the company will analyze the full results as it will design future clinical trials with RUCONEST for the treatment of COVID-19, as well as other serious conditions.
    • 13 Sep 2021 According to a Pharming Group NV media release, study has been concluded and results will be published in peer-review medical journals.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top